Bristol Myers Squibb Company (NYSE:BMY) Shares Bought by AE Wealth Management LLC

Key Points

• AE Wealth Management LLC increased its stake in Bristol Myers Squibb by 11.0%, now owning 68,260 shares worth $4,163,000 as of the latest SEC filing.
• Bristol Myers Squibb reported earnings of $1.80 per share for the last quarter, surpassing analysts' expectations of $1.50, although the revenue decreased by 5.6% year-over-year.
• The company announced a quarterly dividend of $0.62 per share, translating to an annual yield of 5.12%, with a high dividend payout ratio of 92.88%.

AE Wealth Management LLC lifted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 11.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 68,260 shares of the biopharmaceutical company's stock after purchasing an additional 6,754 shares during the quarter. AE Wealth Management LLC's holdings in Bristol Myers Squibb were worth $4,163,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Capital International Investors raised its stake in Bristol Myers Squibb by 7.5% in the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock valued at $2,593,940,000 after purchasing an additional 3,218,865 shares in the last quarter. Geode Capital Management LLC grew its holdings in Bristol Myers Squibb by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock valued at $2,505,967,000 after purchasing an additional 1,187,231 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Bristol Myers Squibb by 59.9% during the 4th quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares during the last quarter. Bank of New York Mellon Corp increased its position in Bristol Myers Squibb by 8.6% during the first quarter. Bank of New York Mellon Corp now owns 26,865,073 shares of the biopharmaceutical company's stock valued at $1,638,501,000 after acquiring an additional 2,131,205 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in Bristol Myers Squibb by 16.2% during the 4th quarter. Northern Trust Corp now owns 24,658,360 shares of the biopharmaceutical company's stock worth $1,394,677,000 after purchasing an additional 3,431,248 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of BMY stock traded down $0.62 during mid-day trading on Tuesday, hitting $46.89. The company had a trading volume of 3,259,641 shares, compared to its average volume of 13,238,002. Bristol Myers Squibb Company has a 52-week low of $44.00 and a 52-week high of $63.33. The company has a market capitalization of $95.42 billion, a P/E ratio of 17.60, a P/E/G ratio of 2.53 and a beta of 0.36. The stock's 50 day moving average price is $47.67 and its 200-day moving average price is $52.53. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.29%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 92.88%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on BMY shares. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price for the company. Wall Street Zen lowered Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. William Blair reiterated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Morgan Stanley decreased their target price on Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating on the stock in a research report on Thursday, July 10th. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $58.53.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.